Huang Chi-Chou, Chien Wen-Pin, Wong Ruey-Hong, Cheng Ya-Wen, Chen Meng-Cheng, Lee Huei
Colorectal Division, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China.
Environ Mol Mutagen. 2009 Mar;50(2):127-33. doi: 10.1002/em.20444.
A recent study conducted by our group showed that the NAT2 fast acetylator genotype is associated with an increasing risk for the development of colorectal cancer (CRC), especially for females. We therefore examined whether a higher risk of CRC in females with the NAT2 fast acetylator genotype was associated with the occurrence of K-RAS mutation, and to further verify whether MGMT promoter methylation was linked to the occurrence of K-RAS mutation in patients with the NAT2 fast acetylator genotype. Herein, 151 CRC cases were examined for NAT2 genetic polymorphisms and MGMT promoter methylation by PCR-RFLP and methylation-specific PCR (MSP). The results of this study show that the NAT2 fast acetylator genotype is associated with the occurrence of K-RAS mutation in female cases (OR = 4.820, 95% CI = 1.113-20.873), but not associated with MGMT promoter methylation. Surprisingly, MGMT promoter methylation significantly deepens the impact of NAT2 fast acetylation on K-RAS mutation in the female cases (OR = 5.129, 95% CI = 1.092-24.105). In conclusion, Taiwanese women with the NAT2 fast acetylator genotype may exhibit a higher risk of CRC with increased occurrence of K-RAS mutation. Detection of NAT2 genotypes and MGMT promoter methylation may be useful in the risk assessment for CRC in Taiwanese women.
我们团队最近进行的一项研究表明,NAT2快速乙酰化基因型与结直肠癌(CRC)发生风险增加有关,尤其是对女性而言。因此,我们研究了携带NAT2快速乙酰化基因型的女性患CRC的较高风险是否与K-RAS突变的发生有关,并进一步验证MGMT启动子甲基化是否与携带NAT2快速乙酰化基因型患者的K-RAS突变发生有关。在此,通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)和甲基化特异性PCR(MSP)检测了151例CRC病例的NAT2基因多态性和MGMT启动子甲基化情况。本研究结果表明,NAT2快速乙酰化基因型与女性病例中K-RAS突变的发生有关(比值比[OR]=4.820,95%置信区间[CI]=1.113-20.873),但与MGMT启动子甲基化无关。令人惊讶的是,MGMT启动子甲基化显著加深了NAT2快速乙酰化对女性病例中K-RAS突变的影响(OR=5.129,95%CI=1.092-24.105)。总之,携带NAT2快速乙酰化基因型的台湾女性可能表现出较高的CRC风险,且K-RAS突变发生率增加。检测NAT2基因型和MGMT启动子甲基化可能有助于台湾女性CRC的风险评估。